Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell

Updated 06/21/2024

Status Recruiting

Clinical Trial Summary

This is an open label, single arm, phase I/II for patients with r/r Non-Hodgkin's Lymphoma . The purpose is to evaluate the safety and efficacy of the combination with Azacytidine, Bendamustine and Piamprizumab

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04897477
Study type	Interventional
Source	Chinese PLA General Hospital
Contact	Weidong Han, M.D.
Phone	+861055499341
Email	hanwdrsw@sina.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	April 22, 2021
Completion date	April 23, 2023

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT05050461` - Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma	N/A
	Recruiting	`NCT06160362` - The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)	N/A
	Recruiting	`NCT04435743` - Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas
	Recruiting	`NCT03720496` - Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy	Phase 1
	Recruiting	`NCT06346912` - CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL	Early Phase 1
	Recruiting	`NCT05518383` - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021	Phase 4
	Recruiting	`NCT02081937` - CART-19 Immunotherapy in Mantle Cell Lymphoma	Phase 1/Phase 2
	Recruiting	`NCT06321289` - Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL	Phase 1/Phase 2
	Not yet recruiting	`NCT05909059` - CAR T-cell Therapy in Patients With Renal Dysfunction	Phase 2
	Recruiting	`NCT05631912` - TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL	Phase 1/Phase 2
	Completed	`NCT04094142` - Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	Phase 2
	Recruiting	`NCT05143112` - Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma	Phase 1/Phase 2
	Recruiting	`NCT04661020` - CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma	Phase 2
	Recruiting	`NCT03497533` - Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19	Phase 1/Phase 2
	Recruiting	`NCT04532268` - A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL	Early Phase 1
	Terminated	`NCT03488251` - PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma	Phase 2
	Recruiting	`NCT05741359` - The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma	Phase 1
	Recruiting	`NCT06156774` - SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project